Skip to Content

UK Edition. Click here for US version.

PRAMIPEXOLE TEVA 1.05 MG PROLONGED-RELEASE TABLETS

Active substance(s): PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE / PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE / PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

View full screen / Print PDF » Download PDF ⇩

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS
1

NAME OF THE MEDICINAL PRODUCT
Pramipexole Teva 1.05 mg Prolonged-release Tablets

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release tablet contains 1.5 mg pramipexole dihydrochloride
monohydrate equivalent to 1.05 mg pramipexole.
Please note:
Pramipexole doses as published in the literature refer to the salt form.
Therefore, doses will be expressed in terms of both pramipexole base and
pramipexole salt (in brackets).
For the full list of excipients, see section 6.1.

3

PHARMACEUTICAL FORM
Prolonged-release Tablet.
Pramipexole Teva 1.05 mg Prolonged-release Tablets: The round tablets of 10
mm diameter are white or nearly white, biconvex and are marked with 105 on
one side

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Pramipexole Teva is indicated in adults for treatment of the signs and
symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in
combination with levodopa, i.e. over the course of the disease, through to late
stages when the effect of levodopa wears off or becomes inconsistent and
fluctuations of the therapeutic effect occur (end of dose or “on off”
fluctuations).

4.2

Posology and method of administration

Pramipexole Teva Prolonged-release Tablets are a once-a-day oral formulation
of pramipexole.
Initial treatment
Doses should be increased gradually from a starting dose of 0.26 mg of base
(0.375 mg of salt) per day and then increased every 5 - 7 days. Providing
patients do not experience intolerable undesirable effects, the dose should be
titrated to achieve a maximal therapeutic effect.
Ascending dose schedule of Pramipexole Teva Prolonged-release Tablets
Week
Daily dose (mg of base)
Daily dose (mg of salt)
1
0.26
0.375
2
0.52
0.75
3
1.05
1.5
If a further dose increase is necessary the daily dose should be increased by
0.52 mg of base (0.75 mg of salt) at weekly intervals up to a maximum dose of
3.15 mg of base (4.5 mg of salt) per day. However, it should be noted that the
incidence of somnolence is increased at doses higher than 1.05 mg of base (1.5
mg of salt) per day (see section 4.8).
Patients already taking pramipexole tablets may be switched to Pramipexole
Teva Prolonged-release Tablets overnight, at the same daily dose. After
switching to Pramipexole Teva Prolonged-release Tablets, the dose may be
adjusted depending on the patient's therapeutic response (see section 5.1).
Maintenance treatment
The individual dose of pramipexole should be in the range of 0.26 mg of base
(0.375 mg of salt) to a maximum of 3.15 mg of base (4.5 mg of salt) per day.
During dose escalation in pivotal studies, efficacy was observed starting at a
daily dose of 1.05 mg of base (1.5 mg of salt). Further dose adjustments
should be done based on the clinical response and the occurrence of adverse
reactions. In clinical trials approximately 5% of patients were treated at doses
below 1.05 mg of base (1.5 mg of salt). In advanced Parkinson's disease,
pramipexole doses higher than 1.05 mg of base (1.5 mg of salt) per day can be
useful in patients where a reduction of the levodopa therapy is intended. It is
recommended that the dose of levodopa is reduced during both the dose
escalation and the maintenance treatment with Pramipexole Teva, depending
on reactions in individual patients (see section 4.5).
Missed dose
When the intake of a dose is missed, Pramipexole Teva Prolonged-release
Tablets should be taken within 12 hours after the regularly scheduled time.
After 12 hours, the missed dose should be left out and the next dose should be
taken on the following day at the next regularly scheduled time.
Treatment discontinuation
Abrupt discontinuation of dopaminergic therapy can lead to the development
of a neuroleptic malignant syndrome. Pramipexole should be tapered off at a
rate of 0.52 mg of base (0.75 mg of salt) per day until the daily dose has been

reduced to 0.52 mg of base (0.75 mg of salt). Thereafter the dose should be
reduced by 0.26 mg of base (0.375 mg of salt) per day (see section 4.4).
Patients with renal impairment
The elimination of pramipexole is dependent on renal function. The following
dose schedule is suggested:
Patients with a creatinine clearance above 50 ml/min require no reduction in
daily dose or dosing frequency.
In patients with a creatinine clearance between 30 and 50 ml/min, treatment
should be started with 0.26 mg Pramipexole Teva Prolonged-release Tablets
every other day. Caution should be exercised and careful assessment of
therapeutic response and tolerability should be made before increasing to daily
dosing after one week. If a further dose increase is necessary, doses should be
increased by 0.26 mg pramipexole base at weekly intervals up to a maximum
dose of 1.57 mg pramipexole base (2.25 mg of salt) per day.
The treatment of patients with a creatinine clearance below 30 ml/min with
Pramipexole Teva Prolonged-release Tablets is not recommended as no data
are available for this patient population. The use of pramipexole tablets should
be considered.
If renal function declines during maintenance therapy, the recommendations
given above should be followed.
Patients with hepatic impairment
Dose adjustment in patients with hepatic failure is probably not necessary, as
approx. 90% of absorbed active substance is excreted through the kidneys.
However, the potential influence of hepatic insufficiency on Pramipexole Teva
pharmacokinetics has not been investigated.
Paediatric population
The safety and efficacy of Pramipexole Teva in children below 18 years has
not been established. There is no relevant use of Pramipexole Teva Prolongedrelease Tablets in the paediatric population in Parkinson's Disease.
Method of administration
The tablets should be swallowed whole with water, and must not be chewed,
divided or crushed. The tablets may be taken either with or without food and
should be taken each day at about the same time.
4.3

Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in
section 6.1.

4.4

Special warnings and precautions for use

When prescribing Pramipexole Teva in a patient with Parkinson's disease with renal
impairment a reduced dose is suggested in line with section 4.2.
Hallucinations
Hallucinations are known as a side effect of treatment with dopamine agonists and
levodopa. Patients should be informed that (mostly visual) hallucinations can occur.
Dyskinesia
In advanced Parkinson's disease, in combination treatment with levodopa, dyskinesia
can occur during the initial titration of Pramipexole Teva. If they occur, the dose of
levodopa should be decreased.
Sudden onset of sleep and somnolence
Pramipexole has been associated with somnolence and episodes of sudden sleep
onset, particularly in patients with Parkinson's disease. Sudden onset of sleep during
daily activities, in some cases without awareness or warning signs, has been reported
uncommonly. Patients must be informed of this and advised to exercise caution while
driving or operating machines during treatment with Pramipexole Teva. Patients who
have experienced somnolence and/or an episode of sudden sleep onset must refrain
from driving or operating machines. Furthermore a reduction of the dose or
termination of therapy may be considered. Because of possible additive effects,
caution should be advised when patients are taking other sedating medicinal products
or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).
Impulse control disorders
Patients should be regularly monitored for the development of impulse control
disorders. Patients and carers should be made aware that behavioural symptoms of
impulse control disorders including pathological gambling, increased libido,
hypersexuality, compulsive spending or buying, binge eating and compulsive
eating can occur in patients treated with dopamine agonists including Pramipexole
Teva. Dose reduction/tapered discontinuation should be considered if such
symptoms develop.
Mania and delirium
Patients should be regularly monitored for the development of mania and delirium.
Patients and carers should be made aware that mania and delirium can occur in
patients treated with pramipexole. Dose reduction/tapered discontinuation should be
considered if such symptoms develop.
Patients with psychotic disorders
Patients with psychotic disorders should only be treated with dopamine agonists if the
potential benefits outweigh the risks. Co-administration of antipsychotic medicinal
products with pramipexole should be avoided (see section 4.5).
Ophthalmologic monitoring
Ophthalmologic monitoring is recommended at regular intervals or if vision
abnormalities occur.
Severe cardiovascular disease
In case of severe cardiovascular disease, care should be taken. It is recommended to
monitor blood pressure, especially at the beginning of treatment, due to the general
risk of postural hypotension associated with dopaminergic therapy.
Neuroleptic malignant syndrome

Symptoms suggestive of neuroleptic malignant syndrome have been reported
with abrupt withdrawal of dopaminergic therapy (see section 4.2).
4.5

Interaction with other medicinal products and other forms of interaction
Plasma protein binding
Pramipexole is bound to plasma proteins to a very low (< 20%) extent, and little
biotransformation is seen in man. Therefore, interactions with other medicinal
products affecting plasma protein binding or elimination by biotransformation are
unlikely. As anticholinergics are mainly eliminated by biotransformation, the
potential for an interaction is limited, although an interaction with anticholinergics
has not been investigated. There is no pharmacokinetic interaction with selegiline and
levodopa.
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%,
presumably by inhibition of the cationic secretory transport system of the renal
tubules. Therefore, medicinal products that are inhibitors of this active renal
elimination pathway or are eliminated by this pathway, such as cimetidine,
amantadine, mexiletine, zidovudine, cisplatin, quinine and procainamide, may
interact with pramipexole resulting in reduced clearance of pramipexole. Reduction
of the pramipexole dose should be considered when these medicinal products are
administered concomitantly with Pramipexole Teva.
Combination with levodopa
When Pramipexole Teva is given in combination with levodopa, it is recommended
that the dose of levodopa is reduced and the dose of other anti-parkinsonian medicinal
products is kept constant while increasing the dose of Pramipexole Teva.
Because of possible additive effects, caution should be advised when patients are
taking other sedating medicinal products or alcohol in combination with pramipexole
(see sections 4.4, 4.7 and 4.8).
Antipsychotic medicinal products
Co-administration of antipsychotic medicinal products with pramipexole should be
avoided (see section 4.4), e.g. if antagonistic effects can be expected.

4.6

Fertility, pregnancy and lactation
Pregnancy
The effect on pregnancy and lactation has not been investigated in humans.
Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at
maternotoxic doses (see section 5.3). Pramipexole Teva should not be used during
pregnancy unless clearly necessary, i.e. if the potential benefit justifies the potential
risk to the foetus.
Breast-feeding
As pramipexole treatment inhibits secretion of prolactin in humans, inhibition of
lactation is expected. The excretion of pramipexole into breast milk has not been
studied in women. In rats, the concentration of active substance-related radioactivity
was higher in breast milk than in plasma.

In the absence of human data, Pramipexole Teva should not be used during breastfeeding. However, if its use is unavoidable, breast-feeding should be discontinued.
Fertility
No studies on the effect on human fertility have been conducted. In animal studies,
pramipexole affected oestrous cycles and reduced female fertility as expected for a
dopamine agonist. However, these studies did not indicate direct or indirect harmful
effects with respect to male fertility.

4.7

Effects on ability to drive and use machines
Pramipexole Teva can have a major influence on the ability to drive and use
machines.
Hallucinations or somnolence can occur.

Patients being treated with Pramipexole Teva and presenting with somnolence
and/or sudden sleep episodes must be informed to refrain from driving or
engaging in activities where impaired alertness may put themselves or others
at risk of serious injury or death (e.g. operating machines) until such recurrent
episodes and somnolence have resolved (see also sections 4.4, 4.5 and 4.8).
4.8

Undesirable effects
Expected adverse reactions
The following adverse reactions are expected under the use of Pramipexole
Teva: abnormal dreams, amnesia, behavioural symptoms of impulse control
disorders and compulsions such as binge eating, compulsive shopping,
hypersexuality and pathological gambling; cardiac failure, confusion,
constipation, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations,
headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate
antidiuretic hormone secretion, insomnia, libido disorders, nausea, paranoia,
peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity;
restlessness, somnolence, sudden onset of sleep, syncope, visual impairment
including diplopia, vision blurred and visual acuity reduced, vomiting, weight
decrease including decreased appetite, weight increase.
Based on the analysis of pooled placebo-controlled trials, comprising a total of
1,778 Parkinson's disease patients on pramipexole and 1,297 patients on
placebo, adverse drug reactions were frequently reported for both groups. 67%
of patients on pramipexole and 54% of patients on placebo reported at least
one adverse drug reaction.
The adverse drug reactions reported in the table below are those events that
occurred in 0.1% or more of patients treated with pramipexole and were
reported significantly more often in patients taking pramipexole than placebo,
or where the event was considered clinically relevant. The majority of adverse
drug reactions were mild to moderate, they usually start early in therapy and
most tended to disappear even as therapy was continued.

Within the system organ classes, adverse reactions are listed under headings of
frequency (number of patients expected to experience the reaction), using the
following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10);
uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (<
1/10,000).
The most commonly (≥ 5%) reported adverse drug reactions in patients with
Parkinson's disease more frequent with pramipexole treatment than with
placebo were nausea, dyskinesia, hypotension, dizziness, somnolence,
insomnia, constipation, hallucination, headache and fatigue. The incidence of
somnolence is increased at doses higher than 1.5 mg pramipexole salt per day
(see section 4.2). A more frequent adverse drug reaction in combination with
levodopa was dyskinesia. Hypotension may occur at the beginning of
treatment, especially if pramipexole is titrated too fast.
System Organ Class
Infections and infestations
Uncommon
Endocrine disorders
Uncommon
Psychiatric disorders
Common

Uncommon

Rare
Nervous system disorders
Very common
Common
Uncommon
Eye disorders
Common

Adverse Drug Reaction
pneumonia
inappropriate antidiuretic hormone secretion1
abnormal dreams, behavioural symptoms of impulse
control disorders and compulsions; confusion,
hallucinations, insomnia
binge eating1, compulsive shopping, delusion,
hyperphagia1, hypersexuality, libido disorder, paranoia,
pathological gambling, restlessness, delirium
mania
dizziness, dyskinesia, somnolence
headache
amnesia, hyperkinesia, sudden onset of sleep, syncope
visual impairment including diplopia, vision blurred and
visual acuity reduced

Cardiac disorders
Uncommon
cardiac failure1
Vascular disorders
Common
hypotension
Respiratory, thoracic, and mediastinal disorders
Uncommon
dyspnoea, hiccups
Gastrointestinal disorders
Very common
nausea
Common
constipation, vomiting
Skin and subcutaneous tissue disorders
Uncommon
hypersensitivity, pruritus, rash
General disorders and administration site conditions
Common
fatigue, peripheral oedema
Investigations

Common
weight decrease including decreased appetite
Uncommon
weight increase
1
This side effect has been observed in post-marketing experience. With 95 %
certainty, the frequency category is not greater than uncommon, but might be lower.
A precise frequency estimation is not possible as the side effect did not occur in a
clinical trial database of 2,762 patients with Parkinson's Disease treated with
pramipexole.
Somnolence
Pramipexole is commonly associated with somnolence and has been
associated uncommonly with excessive daytime somnolence and sudden sleep
onset episodes (see also section 4.4).
Libido disorders
Pramipexole may uncommonly be associated with libido disorders (increased
or decreased).
Impulse control disorders
Pathological gambling, increased libido, hypersexuality, compulsive spending
or buying, binge eating and compulsive eating can occur in patients treated
with dopamine agonists including pramipexole. (See section 4.4).
In a cross-sectional, retrospective screening and case-control study including
3,090 Parkinson's disease patients, 13.6% of all patients receiving
dopaminergic or non-dopaminergic treatment had symptoms of an impulse
control disorder during the past six months. Manifestations observed include
pathological gambling, compulsive shopping, binge eating, and compulsive
sexual behaviour (hypersexuality). Possible independent risk factors for
impulse control disorders included dopaminergic treatments and higher doses
of dopaminergic treatment, younger age (≤ 65 years), not being married and
self-reported family history of gambling behaviours.
Cardiac failure
In clinical studies and post-marketing experience cardiac failure has been
reported in patients with pramipexole. In a pharmacoepidemiological study
pramipexole use was associated with an increased risk of cardiac failure
compared with non-use of pramipexole (observed risk ratio 1.86; 95% CI,
1.21-2.85).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard.
4.9

Overdose

There is no clinical experience with massive overdose. The expected adverse
reactions would be those related to the pharmacodynamic profile of a
dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations,
agitation and hypotension. There is no established antidote for overdose of a
dopamine agonist. If signs of central nervous system stimulation are present, a
neuroleptic agent may be indicated. Management of the overdose may require
general supportive measures, along with gastric lavage, intravenous fluids,
administration of activated charcoal and electrocardiogram monitoring.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Pharmacotherapeutic group: anti-Parkinson drugs, dopamine agonists, ATC code:
N04BC05.
Mechanism of action
Pramipexole is a dopamine agonist that binds with high selectivity and specificity to
the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3
receptors, and has full intrinsic activity.
Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine
receptors in the striatum. Animal studies have shown that pramipexole inhibits
dopamine synthesis, release, and turnover.
Pharmacodynamic effects
In human volunteers, a dose-dependent decrease in prolactin was observed. In a
clinical trial with healthy volunteers, where pramipexole prolonged-release tablets
were titrated faster (every 3 days) than recommended up to 3.15 mg pramipexole base
(4.5 mg of salt) per day, an increase in blood pressure and heart rate was observed.
Such effect was not observed in patient studies.
Clinical efficacy and safety in Parkinson’s disease
In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson's
disease. Placebo-controlled clinical trials included approximately 1,800 patients of
Hoehn and Yahr stages I – V treated with pramipexole. Out of these, approximately
1,000 were in more advanced stages, received concomitant levodopa therapy, and
suffered from motor complications.
In early and advanced Parkinson's disease, efficacy of pramipexole in controlled
clinical trials was maintained for approximately six months. In open continuation
trials lasting for more than three years there were no signs of decreasing efficacy.
In a controlled double blind clinical trial of 2 year duration, initial treatment with
pramipexole significantly delayed the onset of motor complications, and reduced their
occurrence compared to initial treatment with levodopa. This delay in motor
complications with pramipexole should be balanced against a greater improvement in
motor function with levodopa (as measured by the mean change in UPDRS-score).
The overall incidence of hallucinations and somnolence was generally higher in the
escalation phase with the pramipexole group. However, there was no significant
difference during the maintenance phase. These points should be considered when
initiating pramipexole treatment in patients with Parkinson's disease.

The safety and efficacy of pramipexole prolonged-release tablets in the treatment of
Parkinson's disease was evaluated in a multinational drug development program
consisting of three randomised, controlled trials. Two trials were conducted in
patients with early Parkinson's disease and one trial was conducted in patients with
advanced Parkinson's disease.
Superiority of pramipexole prolonged-release tablets over placebo was demonstrated
after 18 weeks of treatment on both the primary (UPDRS Parts II+III score) and the
key secondary (CGI-I and PGI-I responder rates) efficacy endpoints in a double-blind
placebo-controlled trial including a total of 539 patients with early Parkinson's
disease. Maintenance of efficacy was shown in patients treated for 33 weeks.
Pramipexole prolonged-release tablets were non-inferior to pramipexole immediate
release tablets as assessed on the UPDRS Parts II+III score at week 33.
In a double-blind placebo-controlled trial including a total of 517 patients with
advanced Parkinson's disease who were on concomitant levodopa therapy superiority
of pramipexole prolonged-release tablets over placebo was demonstrated after 18
weeks of treatment on both the primary (UPDRS Parts II+III score) and the key
secondary (off-time) efficacy endpoints.
The efficacy and tolerability of an overnight switch from pramipexole tablets to
pramipexole prolonged-release tablets at the same daily dose were evaluated in a
double-blind clinical study in patients with early Parkinson's disease.
Efficacy was maintained in 87 of 103 patients switched to pramipexole prolongedrelease tablets. Out of these 87 patients, 82.8% did not change their dose, 13.8%
increased and 3.4% decreased their dose.
In half of the 16 patients who did not meet the criterion for maintained efficacy on
UPDRS Part II+III score, the change from baseline was considered not clinically
relevant.
Only one patient switched to pramipexole prolonged-release tablets experienced a
drug-related adverse event leading to withdrawal.
Paediatric population

The European Medicines Agency has waived the obligation to submit the
results of studies with pramipexole in all subsets of the paediatric population
in Parkinson's Disease (see section 4.2 for information on paediatric use).
5.2

Pharmacokinetic properties
Absorption
Pramipexole is completely absorbed following oral administration. The absolute
bioavailability is greater than 90%.
In a Phase I trial, where pramipexole immediate release and prolonged-release tablets
were assessed in fasted state, the minimum and peak plasma concentration (Cmin,
Cmax) and exposure (AUC) of the same daily dose of pramipexole prolonged-release
tablets given once daily and pramipexole tablets given three times a day were
equivalent.

The once daily administration of pramipexole prolonged-release tablets causes less
frequent fluctuations in the pramipexole plasma concentration over 24 hours
compared to the three times daily administration of pramipexole immediate release
tablets.
The maximum plasma concentrations occur at about 6 hours after administration of
pramipexole prolonged-release tablets once daily. Steady state of exposure is reached
at the latest after 5 days of continuous dosing.
Concomitant administration with food does generally not affect the bioavailability of
pramipexole. Intake of a high fat meal induced an increase in peak concentration
(Cmax) of about 24% after a single dose administration and about 20% after multiple
dose administrations and a delay of about 2 hours in time to reach peak concentration
in healthy volunteers. Total exposure (AUC) was not affected by concomitant food
intake. The increase in Cmax is not considered clinically relevant. In the Phase III
studies that established safety and efficacy of pramipexole prolonged-release tablets,
patients were instructed to take study medication without regard to food intake.
While body weight has no impact on the AUC, it was found to influence the volume
of distribution and therefore the peak concentrations Cmax. A decreased body weight
by 30 kg results in an increase in Cmax of 45%. However, in Phase III trials in
Parkinson's disease patients no clinically meaningful influence of body weight on the
therapeutic effect and tolerability of pramipexole prolonged-release tablets was
detected.
Pramipexole shows linear kinetics and a small inter-patient variation of plasma levels.
Distribution
In humans, the protein binding of pramipexole is very low (< 20%) and the volume of
distribution is large (400 l). High brain tissue concentrations were observed in the rat
(approx. 8-fold compared to plasma).
Biotransformation
Pramipexole is metabolised in man only to a small extent.
Elimination

Renal excretion of unchanged pramipexole is the major route of elimination.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while
less than 2% is found in the faeces. The total clearance of pramipexole is
approximately 500 ml/min and the renal clearance is approximately 400
ml/min. The elimination half-life (t½) varies from 8 hours in the young to 12
hours in the elderly.
5.3

Preclinical safety data
Repeated dose toxicity studies showed that pramipexole exerted functional effects,
mainly involving the CNS and female reproductive system, and probably resulting
from an exaggerated pharmacodynamic effect of pramipexole.
Decreases in diastolic and systolic pressure and heart rate were noted in the minipig,
and a tendency to a hypotensive effect was discerned in the monkey.

The potential effects of pramipexole on reproductive function have been investigated
in rats and rabbits. Pramipexole was not teratogenic in rats and rabbits but was
embryotoxic in the rat at maternally toxic doses.
Due to the selection of animal species and the limited parameters investigated, the
adverse effects of pramipexole on pregnancy and male fertility have not been fully
elucidated.
A delay in sexual development (i.e., preputial separation and vaginal opening) was
observed in rats. The relevance for humans is unknown.

Pramipexole was not genotoxic. In a carcinogenicity study, male rats
developed Leydig cell hyperplasia and adenomas, explained by the prolactininhibiting effect of pramipexole. This finding is not clinically relevant to man.
The same study also showed that, at doses of 2 mg/kg (of salt) and higher,
pramipexole was associated with retinal degeneration in albino rats. The latter
finding was not observed in pigmented rats, nor in a 2-year albino mouse
carcinogenicity study or in any other species investigated.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Hypromellose
Calcium hydrogen phosphate, anhydrous
Magnesium stearate
Silica, colloidal anhydrous

6.2

Incompatibilities
Not applicable.

6.3

Shelf life
3 years

6.4

Special precautions for storage
This medicinal product does not require any special storage conditions.

6.5

Nature and contents of container
Blister Al/OPA-Al-PVC: 10, 30 and 100 prolonged-release tablets.
Not all pack sizes may be marketed.

6.6

Special precautions for disposal
No special requirements.
Any unused medicinal product or waste material should be disposed of in
accordance with local requirements.

7

MARKETING AUTHORISATION HOLDER
Teva UK Limited
Brampton Road
Hampden Park
Eastbourne
East Sussex
BN22 9AG

8

MARKETING AUTHORISATION NUMBER(S)
PL 00289/1875

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
22/12/2014

10

DATE OF REVISION OF THE TEXT
01/04/2016

Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide